Stockreport

Are Investors Undervaluing Keros Therapeutics, Inc. (NASDAQ:KROS) By 37%? [Yahoo! Finance]

Keros Therapeutics, Inc. - common stock  (KROS) 
PDF The US$88.11 analyst price target for KROS is 5.7% less than our estimate of fair value How far off is Keros Therapeutics, Inc. ( NASDAQ:KROS ) from its intrinsic val [Read more]